Women's Health : Breast Cancer Flashcards

1
Q

What is the most common cancer in the UK?

A

Breast cancer, accounting for 15% of new cancer cases annually.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How many new cases of breast cancer are diagnosed annually in the UK?

A

Approximately 56,000.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

2 types of pre-invasive breast cancer

A

Ductal carcinoma in situ (DCIS) & Lobular carcinoma in situ (LCIS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Ductal carcinoma in situ (DCIS).

A

● Neoplastic proliferation of epithelial cells - confined to duct without invasion through basement membrane. ● Precursor to invasive breast cancer. ● Comedo and non-comedo subtypes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Lobular carcinoma in situ (LCIS).

A

Neoplastic proliferation of epithelial cells, confined to TDLU.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Name some types of Invasive breast cancer

A

Invasive ductal carcinoma, Invasive lobular carcinoma, Medullary carcinoma, Many others - including mucinous, tubular, papillary, inflammatory etc

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Which type of breast cancer is most common?

A

Invasive ductal carcinoma (commonest - 75%). ; Neoplastic proliferation of epithelial cells that invades through the ductal basement membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

medullary carcinoma

A

More prevalent in the younger population. ● Higher grade than IDC.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Invasive carcinoma can be graded using the _________

A

Nottingham criteria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Which 3 components make up the Nottingham criteria

A

○ Gland formation ○ Nuclear atypia / pleomorphism ○ Mitosis counts (indicates rate of cellular reproduction)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

A higher grade carcinoma is one that is markedly different from ___________ and is considered ________.

A

A higher grade carcinoma is one that is markedly different from normal breast tissue and is considered poorly differentiated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What genetic mutation is often linked to breast cancer?

A

BRCA1 mutation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the five steps of metastasis in breast cancer?

A
  1. Invasion through basement membrane 2. Intravasation (entry into circulation) 3. Circulation 4. Extravasation 5. Colonisation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the common sites of breast cancer metastasis?

A

bones, liver, lungs and brain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

List key risk factors for breast cancer.

A
  1. Increasing age 2. Female sex (100:1 F:M incidence) 3. Family history 4. Inherited genetic mutations e.g. BRCA1 5. Endogenous oestrogen exposure: a. Early menarche b. Nulliparity / absence of breastfeeding c. Late menopause 6. Exogenous oestrogen and progestin exposure: a. Systemic hormonal HRT b. Systemic hormonal contraception
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the common symptoms of breast cancer?

A

breast lump

17
Q

What are the common signs of breast cancer

A

nipple discharge, nipple retraction, skin changes e.g. peau d’orange, axillary lymphadenopathy

18
Q

Metatastic features of breast cancer

A

weight loss, bony pain, shortness of breath.

19
Q

What type of staging is used for breast cancer

A

TNM staging (tumour, node, metastasis) -

20
Q

Stage 1A

A

<2cm, isolated to breast

21
Q

Stage 1B

A

<2cm, minor axillary LN spread

22
Q

Stage 2A

A

<2cm, spread to 1-3 ipsilateral LNs.

23
Q

Stage 2B

A

2 - 5cm, minor axillary nodal spread or 2 - 5cm with 1-3 ipsilateral nodes or >5cm, no nodal spread

24
Q

Stage 3A

A

4-9 ipsilateral nodes or >5cm with 1-3 ipsilateral nodes

25
Q

Stage 3B

A

spread to skin / chest wall

26
Q

Stage 3C

A

> 10 axillary nodes or supraclavicular spread or parasternal + axillary spread

27
Q

Stage 4

A

distant metastatic spread to organs.

28
Q

What is the NHS breast cancer screening programme?

A

3-yearly mammogram for women aged 50-71.

29
Q

What are the “2-week wait” criteria for breast cancer referral?

A

○ Unexplained breast lump in a woman aged >30.
○ Unexplained axillary lump in a woman aged >30.
○ Unilateral nipple changes in a woman aged >50.
○ Skin changes suggestive of breast cancer, any age.

30
Q

First line Ix for breast cancer

A

○ >30 or highly suspicious for cancer: mammogram ○ <30: breast ultrasound ○ Plus: ultrasound of the axilla +/- needle biopsy

31
Q

Second line Ix for breast cancer

A

○ Fine needle aspiration and cytology ○ Plus: oestrogen / progesterone receptor testing, HER2 receptor testing

32
Q

Ix : If symptoms / signs suggestive of metastasis

A

CT scan (CT thorax-abdomen-pelvis, CT head).

33
Q

What are mammogram features of invasive carcinoma?

A

Pre-invasive: unifocal / widespread microcalcifications ● Invasive carcinoma: 1. Irregular spiculated mass 2. Clustered microcalcifications 3. Linear branching calcifications.

34
Q

What is the first-line surgical treatment for breast cancer?

A

Tumour excision or mastectomy +/- breast reconstruction ○ Plus sentinel lymph node biopsy (no evidence of nodal spread) or axillary node clearance

35
Q

When is radiotherapy used in breast cancer management?

A

After surgery, especially for invasive cancers. radiotherapy
○ Whole breast / partial-breast
○ If tumour is invasive (i.e. not DCIS, LCIS), systemic third line therapy is indicated

36
Q

What systemic therapies are used for breast cancer?

A

: systemic therapy (guided by the PREDICT tool); oestrogen-receptor positive, HER2, chemotherapy. - systemic therapies can be neoadjuvant i.e. used to reduce tumour size before attempting surgery.

37
Q

Oestrogen-receptor positive:

A

■ Pre-menopausal / male - tamoxifen (anti-oestrogen) ■ Post-menopausal - anastrozole / letrozole (aromatase inhibitor, prevents peripheral oestrogen synthesis) ■ Note - tamoxifen therapy can be continued long-term (5 years) before
switching to an aromatase inhibitor.

38
Q

HER2 (human epidermal growth factor receptor 2) positive:

A

Trastuzumab (Herceptin)

39
Q

Chemotherapy:

A

■ Including a taxane and an anthracycline ■ E.g. ACT: doxorubicin, cyclophosphamide and paclitaxel